Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

82.40EUR
19 Oct 2018
Change (% chg)

€0.40 (+0.49%)
Prev Close
€82.00
Open
€81.60
Day's High
€82.85
Day's Low
€80.50
Volume
56,700
Avg. Vol
88,784
52-wk High
€99.20
52-wk Low
€65.05

Latest Key Developments (Source: Significant Developments)

Diasorin SpA Receives CE Marking For Its New Simplexa VZV Direct assay
Friday, 12 Oct 2018 08:33am EDT 

Oct 12 (Reuters) - DiaSorin SpA ::ANNOUNCED TO HAVE RECEIVED CE MARKING FOR ITS NEW SIMPLEXA VZV DIRECT ASSAY.  Full Article

Diasorin Launches New Liaison Quantiferon-TB Gold Plus In Partnership With Qiagen
Monday, 17 Sep 2018 01:27am EDT 

Sept 17 (Reuters) - Diasorin Spa ::LAUNCHES NEW LIAISON QUANTIFERON-TB GOLD PLUS ASSAY AS AN AID FOR LATENT TUBERCULOSIS DETECTION IN PARTNERSHIP WITH QIAGEN.SAYS TEST WAS DEVELOPED IN A PARTNERSHIP BETWEEN DIASORIN AND QIAGEN.SAYS TEST WILL BE LAUNCHED IN U.S. BY 2019 AND IN CHINA BY 2020.  Full Article

DiaSorin Q1 Net Profit Up At EUR 38.3 Mln
Tuesday, 8 May 2018 06:29am EDT 

May 8 (Reuters) - DiaSorin SpA ::Q1 REVENUE EUR 164.5 MILLION VERSUS EUR 157.5 MILLION YEAR AGO.Q1 NET PROFIT EUR 38.3 MILLION VERSUS EUR 32.9 MILLION YEAR AGO.SEES 2018 REVENUES GROWTH OF ABOUT 11 PERCENT AT CER (CONSTANT CURRENCIES) COMPARED TO THE 2017 FINANCIAL YEAR.SEES 2018 EBITDA GROWTH OF ABOUT 13 PERCENT AT CER (CONSTANT CURRENCIES) COMPARED TO THE 2017 FINANCIAL YEAR.  Full Article

DiaSorin FY Net Profit Up At EUR 139.9 Mln
Wednesday, 7 Mar 2018 08:17am EST 

March 7 (Reuters) - DIASORIN SPA ::FY REVENUE EUR 637.5 MILLION VERSUS EUR 569.3 MILLION YEAR AGO.FY NET PROFIT EUR 139.9 MILLION VERSUS EUR 112.6 MILLION YEAR AGO.SAYS PROPOSED ORDINARY DIVIDEND OF € 0.85 PER SHARE AND SPECIAL DIVIDEND OF € 1.80 PER SHARE.2018 GUIDANCE: REVENUES AROUND +11% AT CER COMPARED WITH 2017.2018 GUIDANCE: EBITDA AROUND +13% AT CER COMPARED WITH 2017.  Full Article

Qiagen, DiaSorin partner in automated tuberculosis detection
Monday, 8 Jan 2018 02:00am EST 

Jan 8 (Reuters) - Qiagen Nv ::SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​.SAYS ‍DIASORIN TO ADD NOVEL CONTENT TO ALREADY BROAD LIAISON MENU, OVER 7,000 SYSTEMS INSTALLED​.SAYS ‍ANNOUNCES MILESTONE OF OVER 40 MILLION QUANTIFERON-TB TESTS SINCE LAUNCH​.  Full Article

Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis
Monday, 8 Jan 2018 01:56am EST 

Jan 8 (Reuters) - DIASORIN SPA ::ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS.UNDER AGREEMENT, PARTIES ARE DEVELOPING FULLY AUTOMATED VERSION OF QUANTIFERON TEST READ-OUT COMPONENTS.  Full Article

DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance
Thursday, 9 Nov 2017 07:07am EST 

Nov 9 (Reuters) - DIASORIN SPA ::Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO.Q3 NET PROFIT EUR 29.3‍​ MILLION VERSUS EUR 28.7 MILLION YEAR AGO.REAFFIRMS ITS FY'17 GUIDANCE‍​.  Full Article

Diasorin revises its FY 2019 guidance
Friday, 29 Sep 2017 07:03am EDT 

Sept 29 (Reuters) - DIASORIN SPA ::INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION.INCREASES ITS 2019 EBITDA GUIDANCE TO EUR 295-300 MILLION FROM EUR 280-285 MILLION.INCREASES ITS 2019 NET PROFIT GUIDANCE TO EUR 160-165 MILLION FROM EUR 155-160 MILLION.REVISES ITS GUIDANCE AS CONSEQUENCE OF COMPLETION OF ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS.  Full Article

DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​
Friday, 29 Sep 2017 06:19am EDT 

Sept 29 (Reuters) - DIASORIN SPA ::‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​.  Full Article

DiaSorin Q2 net profit up at EUR 33.6 mln
Thursday, 3 Aug 2017 06:40am EDT 

Aug 3 (Reuters) - DIASORIN SPA ::Q2 NET PROFIT EUR 33.6 MILLION VERSUS EUR 29.4 MILLION YEAR AGO.Q2 REVENUE EUR 161.8 MILLION VERSUS EUR 141.7 MILLION YEAR AGO.KEEPS UNCHANGED THE PREVIOUS GUIDANCE ON REVENUES AND REVISES UPWARDS THE PREVIOUS GUIDANCE ON EBITDA FOR 2017.SEES FY 2017 EBITDA GROWTH EQUAL TO ABOUT +13% AT CER (CONSTANT EXCHANGE RATE) COMPARED WITH 2016 (PREVIOUS GUIDANCE: GROWTH EQUAL TO ABOUT +11% AT CER).  Full Article